Group 1 - The core viewpoint of the news highlights the strong support from the government for the development of innovative drugs, as evidenced by the release of 16 supportive policies by the National Healthcare Security Administration and the Health Commission [1] - The approval of Shuwotini by Dize Pharmaceutical as the first domestically developed EGFR exon 20 insertion NSCLC drug to be approved in the U.S. underscores the international competitiveness of domestic innovative drugs [1] - The biopharmaceutical sector has shown strong performance, significantly outperforming the broader market index, with a year-to-date increase of 7.09% and a recent weekly increase of 4.40% [1] Group 2 - The biopharmaceutical ETF tracks the CS Biomedicine Index, which includes listed companies involved in biotechnology and medical devices, reflecting the overall performance of the biopharmaceutical sector [2] - The index covers multiple sub-sectors, showcasing high growth and innovation characteristics within the biopharmaceutical and medical device industries [2]